Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Interictal burden should be considered in the medical care of people with migraine. This additional burden is holistic, with psychosocial and socioeconomic elements in addition to residual symptoms. It is essential to consider this when assessing the impact of IIB.
Authors
- Elizabeth K. Seng (ORCID: https://orcid.org/0000-0002-8938-4949)
- William R. Lenderking
- Margaret Hoyt (ORCID: https://orcid.org/0000-0002-9486-2095)
- Mary Kate Ladd
- Karen G. Malley
- Maurice Vincent (ORCID: https://orcid.org/0000-0001-5855-6069)
- Lars Viktrup (ORCID: https://orcid.org/0000-0002-8739-0544)
- Christian Lampl (ORCID: https://orcid.org/0000-0003-4340-3486)
- Lucinda Hetherington
- Jun Chen (ORCID: https://orcid.org/0009-0003-1494-1418)
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Albert Einstein College of Medicine (US)
- Eli Lilly (United States) (US)
- Convent Hospital of the Brothers of Saint John of God (AT)
- EVRAZ (United Kingdom) (GB)
Publication Details
- Journal
- The Journal of Headache and Pain
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s10194-024-01927-8
- Citations
- 6
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.31
Funders
- Eli Lilly and Company